Tag: M.W:100-200

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

62937-45-5, General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.54258-41-2,1,10-Phenanthrolin-5-amine,as a common compound, the synthetic route is as follows.

54258-41-2, General procedure: Both compounds were synthesized in the same way. A mixture ofthe appropriate aldehyde [thiophene-2,5-dicarbaldehyde (283 mg,2.02 mmol), furan-2,5-dicarbaldehyde (316 mg, 2.55 mmol)] and5-amino-1,10-phenanthroline [(1091 mg, 5.59 mmol) withthiophene-2,5-dicarbaldehyde, (1458 mg, 7.48 mmol) with furan-2,5-dicarbaldehyde] was refluxed in EtOH (50 mL) containing acatalytic amount of acetic acid for 12 h, giving a suspension. Thereaction mixture was filtered hot, and the solid was washed withEtOH to afford the desired product as a yellow solid.N,N0-[thiophene-2,5-diylbis(methan-1-yl-1-ylidene)]bis(1,10-phenanthroline-5-amine): Yield 926 mg, 92.8%. 1H NMR (400 MHz,CDCl3): d = 7.44 (s, 2H), 7.65 (dd, J = 8.0, 4.4 Hz, 2H), 7.69 (s, 2H),7.72 (dd, J = 8.0, 4.4 Hz, 2H), 8.27 (dd, J = 8.4, 1.6 Hz, 2H), 8.87(dd, J = 8.0, 1.6 Hz, 2H), 8.90 (s, 2H), 9.17 (dd, J = 4.4, 1.6 Hz, 2H),9.26 (dd, J = 4.4, 2.0 Hz, 2H). ESI-MS: m/z = 495.3 [M+H]+. IR mmax(KBr, cm1): 3423 (br), 1590 s, 1563m, 1503w, 1485w, 1423m,1384 s, 1239m, 1204w, 1143w, 1110w, 1060m, 973w, 874w,802w, 743m, 627w, 523w, 414w.

54258-41-2 1,10-Phenanthrolin-5-amine 606970, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Cheng, Feixiang; He, Chixian; Yu, Shiwen; Yin, Hongju; Inorganica Chimica Acta; vol. 462; (2017); p. 43 – 49;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

33454-82-9, Lithium trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The 2.21 g (10 mmol) 1-methylpyrrolidinium-l-butanesulfonate obtained in the example 2 was put in methanol, added with a solution obtained by dissolving lithium triflate 1.56 g (10 mmol) in methanol and then stirred for 12 hours. After that, the mixture solution was filtered and washed with methanol for several times and then dried, thereby providing triflate lithium 1-methylpyrrolidinium-1-butanesulfonate with 96% yields which was white solids of zwitterions.

33454-82-9, As the paragraph descriping shows that 33454-82-9 is playing an increasingly important role.

Reference£º
Patent; Korea Institute of Science and Technology; WO2006/104305; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33454-82-9,Lithium trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

General procedure: N-alkylated product of di/trimeric imidazolium bromide (1.0 equi.)is treated with NaBF4/KPF6/LiCF3SO3 (3.05 equi.) in the presence of10 mL of deionized water at room temperature with stirring for about1 h afforded the anion exchanged product of di/trimeric imidazoliumcation with different anions. After the anion exchanged reaction,Soxhlet extractions is done to removemetallic bromide fromdi/trimericimidazolium salts using 100 mL of dry THF for about 1 h reflux to giverespective imidazolium salt in quantitative yield, 33454-82-9

The synthetic route of 33454-82-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Ganapathi, Pandurangan; Ganesan, Kilivelu; Journal of Molecular Liquids; vol. 233; (2017); p. 452 – 464;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5,4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a solution of 1,4,7-triazacyclononane (2 mmol) in distilled ethanol (50 mL) containing molecular sieve was added 1 equiv of aldehyde. The reaction mixture was stirred at room temperature. The solution was filtered and the filtrate was evaporated under reduced pressure to yield the aminal adduct.

As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.

Reference£º
Article; Roger, Melissa; Patinec, Veronique; Bourgeois, Martine; Tripier, Raphael; Triki, Smail; Handel, Henri; Tetrahedron; vol. 68; 27-28; (2012); p. 5637 – 5643;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

1,4,7-Triazatricyclo[5.2.1.0410]decane (Orthoamide) 0.5 mol 1,4,7-triazacyclononane, 64.3 g, 0.54 mol orthoformicacidtriethylester, 74.8 g, and 20 mmol p-toluolsulphonacid, 4 g, are heated to 150 C. The ethanol that is created and some of the esters are distilled off. After the reaction has been completed the orthoamide can be distilled off at a pressure of <80 mbar in the form of a bright yellow volatile oil (b.p. 350 K at 133 Pa), in agreement with literature (T. J. Atkins, J. Am. Chem. Soc., 102, 6365 (1980)). 4730-54-5, The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Unilever Home & Personal Care USA, division of Conopco, Inc.; US6646122; (2003); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23195-62-2,2-(1H-1,2,4-Triazol-3-yl)pyridine,as a common compound, the synthetic route is as follows.

A BMes2-functionalized phenyl-triazole (3a) ligand (0.10 mmol) and [PtMe2(u-SMe2)]2 (0.032 g, 0.055 mmol) were added to a 20 mL screw-cap vial with of acetone (5 mL). The resulting mixture was heated to and maintained at 75 C for 2 hours. Then, a 0.10 M solution of TsOH in THF (1 mL) was added. The resulting solution was stirred for 1 hour. Next, 0.1 M solution of 2-(1 H-1 ,2,4-triazol-3-yl)pyridine in methanol (2 mL) was added and the mixture was stirred overnight. The solvent was then removed under reduced pressure. The crude product was dissolved in methanol and purified on TLC plate using acetone as the eluent.

23195-62-2, The synthetic route of 23195-62-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; QUEEN’S UNIVERSITY AT KINGSTON; WANG, Suning; HUDSON, Zachary, M.; WANG, Xiang; WO2014/138912; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,4730-54-5

Example 10Synthesis of l,4,7-tris{[6′-ethoxycarbonyl-4′-(4″-methoxycarbonyl-l ‘-methylpyrrol- 5 ‘ ‘ -yl)pyridine-2 ‘ -yljmethyl} – 1 ,4,7-triazacyclononane (9); A mixture of compound 9 (35 mg, 0.104 mmol), 1,4,7-triazacyclononane (4.4 mg, 0.034), potassium carbonate (29 mg, 0.208 mmol) and DMF (2 ml) was stirred overnight at room temperature. The reaction mixture was filtered, evaporated to dryness and the product purified by preparative TLC (15 % EtOH/CH2Cl2 + 1% TEA). Yield was 20 mg (57 %).

The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; WALLAC OY; KETOLA, Janne; HOVINEN, Jari; WO2010/55207; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

33454-82-9, Lithium trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: 1-Methoxy/1,6-dimethoxy pyridinium bromide (1.0 equiv./1.784×10-3 mmol) and 1.03 equiv. inorganic salt (NaBF4, K4PF6, and LiCF3SO3) are mixed with 10 mL of deionized water at room temperature with stirring for about 1 h to give anion exchanged products 3-8., 33454-82-9

The synthetic route of 33454-82-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Manikandan, Chitrarasu; Ganesan, Kilivelu; Synthetic Communications; vol. 44; 23; (2014); p. 3362 – 3367;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

62937-45-5, General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI